Data gathered: October 23
AI Stock Analysis - Gilead Sciences (GILD)
Analysis generated October 11, 2025. Powered by Chat GPT.
Gilead Sciences is a biopharmaceutical company primarily focused on antiviral drugs used in the treatment of HIV, Hepatitis B, and Influenza, among other diseases. With a history of strong drug portfolio performance, the company commands significant market share in the antiviral segment. Known for its innovation and robust R&D pipeline, Gilead continues to seek breakthroughs in new therapeutic areas.
Stock Alerts - Gilead Sciences (GILD)
 |
Gilead Sciences | October 17 Insider Alert: Mercier Johanna is selling shares |
|
Gilead Sciences | October 10 Val Hoyle (member of U.S. congress) is selling shares |
|
Gilead Sciences | October 1 Insider Alert: O'Day Daniel Patrick is selling shares |
|
Gilead Sciences | September 17 Insider Alert: Mercier Johanna is selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Gilead Sciences
About Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
| Price | $120.74 |
| Target Price | Sign up |
| Volume | 4,630,000 |
| Market Cap | $154B |
| Year Range | $95.55 - $124.08 |
| Dividend Yield | 2.53% |
| PE Ratio | 24.62 |
| Analyst Rating | 62% buy |
| Earnings Date | October 30 '25 |
| Industry | Biotechnology |
In the news
 |
What to Expect From Gilead Sciences' Next Quarterly Earnings ReportOctober 22 - Biztoc.com |
 |
Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To RunOctober 18 - SeekingAlpha |
 |
A Look at Gilead Sciences’s Valuation Following Breakthrough HIV and Cancer Clinical Trial ResultsOctober 17 - Yahoo |
Gilead Sciences Inc. stock outperforms competitors on strong trading dayOctober 17 - MarketWatch |
|
|
RBC Warns Gilead (GILD) Faces Risk from Trump’s Price Cut TargetOctober 16 - Yahoo |
|
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowOctober 15 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 7.08B | 1.5B | 5.58B | 1.96B | 3.37B | 2.010 |
| Q1 '25 | 6.67B | 1.54B | 5.13B | 1.32B | 2.61B | 1.810 |
| Q4 '24 | 7.57B | 1.58B | 5.99B | 1.78B | 3.11B | 1.900 |
| Q3 '24 | 7.55B | 1.57B | 5.97B | 1.25B | 1.88B | 2.020 |
| Q2 '24 | 6.95B | 1.54B | 5.41B | 1.61B | 2.98B | 2.010 |
Insider Transactions View All
| Dickinson Andrew D filed to sell 157,055 shares at $118.1. October 16 '25 |
| Mercier Johanna filed to sell 110,193 shares at $118.1. October 16 '25 |
| O'Day Daniel Patrick filed to sell 591,203 shares at $112.4. September 30 '25 |
| O'Day Daniel Patrick filed to sell 593,164 shares at $111.5. September 30 '25 |
| Dickinson Andrew D filed to sell 159,555 shares at $113.6. September 16 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Val Hoyle |
Oct 10, 25 | Sell | $1K - $15K |
| Valerie Hoyle |
Sep 12, 25 | Buy | $1K - $15K |
| Marjorie Taylor Greene |
Jun 19, 25 | Buy | $1K - $15K |
Read more about Gilead Sciences (GILD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Gilead Sciences?
The Market Cap of Gilead Sciences is $154B.
What is Gilead Sciences' PE Ratio?
As of today, Gilead Sciences' PE (Price to Earnings) ratio is 24.62.
When does Gilead Sciences report earnings?
Gilead Sciences will report its next earnings on October 30 '25.
What is the current stock price of Gilead Sciences?
Currently, the price of one share of Gilead Sciences stock is $120.74.
How can I analyze the GILD stock price chart for investment decisions?
The GILD stock price chart above provides a comprehensive visual representation of Gilead Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gilead Sciences shares. Our platform offers an up-to-date GILD stock price chart, along with technical data analysis and alternative data insights.
Does GILD offer dividends to its shareholders?
Yes, Gilead Sciences (GILD) offers dividends to its shareholders, with a dividend yield of 2.53%. This dividend yield represents Gilead Sciences' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Gilead Sciences in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Gilead Sciences?
Some of the similar stocks of Gilead Sciences are Amgen, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.
